Table 1. Baseline characteristics of patients with TP53mut ctDNA and CA 125 monitoring (n=28).
| Variables | Value | |
|---|---|---|
| Age at diagnosis (yr) | 54.6 (49–62) | |
| Follow-up duration (mo) | 31.7 (27.2–37.5) | |
| Pretreatment TP53MAC (copies/µL) | 6.9 (2.2–18.9) | |
| Pretreatment CA 125 (U/mL) | 1,416.5 (904–2,165) | |
| Pretreatment tumor volume (cm3) | 708.9 (353–1,191) | |
| TTP (mo) | 16.9 (11.6–22) | |
| PFS (mo) | 23.0 (17.3–28.6) | |
| Primary site | ||
| Ovarian cancer | 12 (42.9) | |
| Tubal cancer | 12 (42.9) | |
| Primary peritoneal carcinoma | 4 (14.3) | |
| Initial FIGO stage | ||
| II | 2 (7.1) | |
| III | 16 (57.1) | |
| IV | 10 (35.7) | |
| Primary debulking surgery | ||
| R0 (No residual) | 9 (32.1) | |
| Optimal (<1 cm) | 8 (28.6) | |
| Sub-optimal (>1 cm) | 11 (39.3) | |
| Adjuvant chemotherapy cycles | ||
| 6 | 17 (60.7) | |
| 7–9 | 9 (32.1) | |
| 10–12 | 2 (7.1) | |
| Adjuvant chemotherapy response | ||
| CR | 21 (75.0) | |
| PR | 5 (17.9) | |
| SD | 1 (3.6) | |
| PD | 1 (3.6) | |
| Recur | ||
| Yes | 19 (67.9) | |
| No | 9 (32.1) | |
Values are presented as median (interquartile range) or number (%).
CA 125, cancer antigen 125; CR, complete response; ctDNA, circulating tumor DNA; FIGO, International Federation of Gynecology and Obstetrics; PD, progressive disease PFS, progression-free survival; PR, partial response; SD, stable disease; TP53MAC, TP53 mutant allele count; TP53mut, TP53 mutation; TTP, time to progression.